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WHO has targeted yaws for global eradication by 2020. The program goals are to interrupt the transmission in countries where
yaws is endemic and to certify countries as yaws free where yaws was endemic in the past. No new rapid plasmin reagin (RPR)
seroreactivity in young children is required for certification of elimination at a country level. We sought to evaluate whether
antibody responses to specific treponemal antigens measured in a high-throughput multiplex bead array (MBA) assay differenti-
ate past versus current infection and whether a nontreponemal lipoidal antigen test can be incorporated into the MBA. Serum
and dried blood spot specimens collected for yaws surveillance projects in Ghana, Vanuatu, and Papua New Guinea (PNG) were
run on MBA to measure antibodies against recombinant p17 (rp17) and treponemal membrane protein A (TmpA) treponemal
antigens. Results were compared to standard treponemal laboratory (TPPA or TPHA [TPP(H)A]) and quantitative RPR test
data. Of 589 specimens, 241 were TPP(H)A/RPR, 88 were TPP(H)A/RPR, 6 were TPP(H)A/RPR, and 254 were negative
for both tests. Compared to TPP(H)A, reactive concordance of rp17 was 93.7%, while reactive concordance of TmpA was only
81.9%. TmpA-specific reactivity showed good correlation with RPR titers (R2  0.41; P < 0.0001). IgG responses to the lipoidal
antigen used in RPR testing (cardiolipin) were not detected in the MBA. Our results suggest that TmpA can be used as a trepone-
mal antigen marker for recent or active infection and potentially replace RPR in a high-throughput multiplex tool for large-scale
yaws surveillance.
Yaws is an infectious disease caused by Treponema pallidum ssp.pertenue, which mainly affects children in rural communities
in the humid tropics (1, 2). This bacterium causes a chronic re-
lapsing disease characterized by highly contagious primary and
secondary cutaneous lesions and noncontagious tertiary destruc-
tive lesions of the bones. It is spread by skin-to-skin contact and is
not sexually transmitted but cannot be distinguished serologically
from syphilis (3).
Clinical features alone are not reliable indicators of yaws infec-
tion, with recent surveys indicating that only 30% to 60% of all
suspected skin ulcers were seroreactive using conventional sero-
logical tests for syphilis (4, 5). Therefore, diagnosis of yaws typi-
cally requires confirmatory serological testing. Typically, a sero-
logical diagnosis for yaws is based on the detection of two distinct
antibodies: one against a treponemal antigen that indicates cur-
rent or previous exposure to infection, such as the Treponema
pallidum particle agglutination (TPPA) and hemagglutination
(TPHA) assays, and one against cardiolipin, a nontreponemal an-
tigen that can be quantitatively measured by tests, such as the
rapid plasma reagin (RPR) and Venereal Disease Research Labo-
ratory (VDRL) tests, that are better able to discriminate between
current active disease and past infections.
WHO has targeted yaws eradication by 2020 and has developed
the Morges strategy, which is comprised of mapping the disease at
a community level and subsequently treating the entire popula-
tion of communities in which yaws is endemic with single-dose
azithromycin (5, 6). The efficacy of this approach was demon-
strated in a study of mass treatment in Papua New Guinea (PNG)
(5) and in Vanuatu and a subdistrict of southern Ghana (A. Pillay,
C. Chen, and T. Ye, unpublished data). The program goals are to
interrupt transmission in all countries where the disease is cur-
rently endemic and to certify that all previously countries where
the disease was endemic are yaws free. Certification of elimination
at a country level is determined by zero reporting of yaws cases and
by lack of RPR seroreactivity in young children, because reactivity
of nontreponemal tests is a better indicator of recent infection
than reactivity of treponemal tests. Unfortunately, the RPR test
cannot be automated for use in large-scale serosurveys.
A large-scale serosurveillance tool for use in stand-alone sur-
veys or in conjunction with serosurveillance for other neglected
tropical diseases (NTDs) is required to direct mapping efforts and
to certify elimination of yaws (7–10). Ideally, this tool would be
able to differentiate previous from current treponemal infection.
We therefore sought to evaluate serological testing for yaws by use
of two recombinant treponemal antigens, the recombinant p17
(rp17) antigen and the treponemal membrane protein A (TmpA)
on a multiplex bead array (MBA) assay, which is capable of mea-
suring multiple analytes in a single run. These data were compared
Received 22 September 2015 Returned for modification 4 January 2016
Accepted 18 February 2016
Accepted manuscript posted online 9 March 2016
Citation Cooley GM, Mitja O, Goodhew B, Pillay A, Lammie PJ, Castro A, Moses P,
Chen C, Ye T, Ballard R, Martin DL. 2016. Evaluation of multiplex-based antibody
testing for use in large-scale surveillance for yaws: a comparative study. J Clin
Microbiol 54:1321–1325. doi:10.1128/JCM.02572-15.
Editor: R. Patel
Address correspondence to Diana L. Martin, hzx3@cdc.gov.
* Present address: Brook Goodhew, University of Miami, Miami, Florida, USA.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/JCM.02572-15.
Copyright © 2016 Cooley et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution 4.0 International license.
crossmark
May 2016 Volume 54 Number 5 jcm.asm.org 1321Journal of Clinical Microbiology
to reference standards and correlated with results obtained quan-
titatively against the RPR test. Some evidence suggests that anti-
body titers to certain treponemal antigens, primarily TmpA, de-
cline rapidly following treatment for syphilis (11, 12). TmpA may
therefore be a potential candidate antigen to measure the impact
of yaws elimination efforts. A secondary aim of our study was to
evaluate the performance of the nontreponemal antigen cardioli-
pin when linked to beads on the MBA assay.
MATERIALS AND METHODS
Study population and ethics statement. Specimens were collected as part
of various yaws evaluation studies in Ghana, Vanuatu, and PNG in 2013.
In Ghana, serum samples were collected from children aged 5 to 14 years
as part of a baseline assessment of the prevalence of yaws. In Vanuatu,
whole blood was collected from children aged 5 to 14 years onto filter
paper (TropBio Pty Ltd., Queensland, Australia) and then allowed to air
dry at least 4 h to form dried blood spots (DBS). DBS were collected from
children with clinically suspected yawslike lesions as part of the baseline
assessment of the prevalence of yaws in schoolchildren from randomly
selected primary schools. In PNG, serum samples were collected from
children aged 1 to 14 years during serological surveys for latent yaws, as
described elsewhere (5). The studies were reviewed and approved by the
Ghana Health Service Ethical Review Committee for Ghana; by the Min-
istry of Health in Vanuatu, WHO, and the CDC for Vanuatu; and by the
Medical Research Advisory Committee of the Papua New Guinea Minis-
try of Health for PNG. All identifiers were removed prior to shipment to
CDC for serological testing, and CDC staff members were determined to
be nonengaged in human subject research.
Serological testing. Blood specimens were tested for seroreactivity
using the TPPA test (used in Ghana and Vanuatu; Fujirebio Diagnostics,
Malvern, PA,), the TPHA test (used in PNG; Human Diagnostics, Wies-
baden, Germany) (for brevity, we refer to the treponemal testing as
TPP[H]A), and a quantitative RPR test (Alere Wampole, Waltham, MA,
for Ghana and Vanuatu; Human Diagnostics, Wiesbaden, Germany, for
PNG). All assays were performed according to the manufacturers’ in-
structions. RPR data were recorded as titers: RPR negative, R1 (positive
using neat serum), R2 (positive at 1:2 dilution), R4 (1:4), R8 (1:8), R16
(1:16), R32 (1:32), R64 (1:64), or R128 (1:128).
Antigen bead coupling.
Proteins. Recombinant glutathione S-transferase (GST)-tagged rp17
(Chembio Diagnostic Systems, Inc., Medford, NY) and full-length re-
combinant TmpA (ViroGen, Watertown, MA) were provided as a 114-
kDa fusion at the N terminus with -galactosidase. Both rp17 and TmpA
were dialyzed overnight at 4°C into phosphate-buffered saline (PBS). An-
tigens were coupled to polystyrene microspheres (SeroMap beads; Lu-
minex Corporation, Austin, TX) as previously described (1). Briefly, car-
boxyl groups on the beads were chemically modified to ester groups by
1-ethyl-3(3-dimethlaminopropyl) carbodiimide (EDC) (Calbiochem,
San Diego, CA) in the presence of N-hydroxysulfosuccinimide (NHS)
(Pierce, Rockford, IL). Primary amine groups on the antigens were then
reacted with ester groups on the beads to create amide covalent bonds.
Antigen-coupled beads were quantified by hemocytometer and stored at
4°C with PBS containing 1% bovine serum albumin (BSA) plus protease
inhibitors.
Cardiolipin. Poly-L-lysine (Sigma-Aldrich Co. LLC., St. Louis, MO)
and cadavarine (Sigma-Aldrich) were tested as diamine linkers to conju-
gate the carboxylated cardiolipin (Avanti Polar Lipids, Inc., Alabaster, AL)
to the carboxylated polystyrene beads. Poly-L-lysine and cadavarine were
serially diluted in 0.1 M NaH2PO4 (pH 5.6) (NaP) to four different con-
centrations (1,000, 250, 62.5, and 15.6 g/ml) for a total of eight amina-
tion conditions. Polystyrene beads (106) were pelleted and washed two
times with NaP and activated in 200 l NaP plus 60 mg/ml EDC and 20
mg/ml NHS. Beads were incubated for 30 min at room temperature (RT)
with EDC and NHS, and then 100 l of each amination condition was
added and incubated for 1 h at RT with shaking. Beads were then blocked
with PBS plus 1% BSA, washed with PBS, and suspended in 100 l PBS
(pH 7.2). Carboxylated cardiolipin was activated by incubation with 200
l of 60 mg/ml EDC and 100 l of 20 mg/ml NHS for 1 h at RT. Activated
cardiolipin was coupled to amine beads by incubating 100 l of activated
cardiolipin with 100 l of amine beads for 2 h at RT with stirring. Beads
were then washed and resuspended in bead storage buffer and stored at
4°C until use.
Blood spot and serum preparation. One blood spot extension (cali-
brated to hold 10 l whole blood) was eluted overnight at 4°C with
2,000 l PBS containing 0.5% casein (Sigma C7078), 0.05% Tween 20,
0.02% sodium azide, 0.5% polyvinyl alcohol (PVA), 0.8% polyvinylpyr-
rolidone (PVP), and 3 g/ml Escherichia coli crude extract containing
recombinant GST (PCN-EC) for a final whole-blood dilution of 1:400 of
eluted sera (assuming that 50% of DBS content is serum). Serum samples
were diluted 1:400 in 500 l PCN-EC. Dilutions were incubated at 37°C
for 1 h to increase the effectiveness of the E. coli extract absorption of
nonspecific antibodies. Dilutions were stored at 4°C and centrifuged at
16,000  g immediately before use. For cardiolipin, serum samples were
diluted in PCN-EC at 1:6, 1:25, 1:100, and 1:400.
Multiplex bead assay. Blood spot eluates and diluted sera were run on
the Luminex 200 as previously described (1). For detection of rp17 or
TmpA-specific IgG, samples were incubated with antigen-coated micro-
spheres; then, following removal of serum, bound antibody was detected
with biotinylated anti-human IgG and anti-human IgG4 antibodies and
detected using streptavidin-conjugated phycoerythrin (PE). The fluores-
cent signal emitted by the PE was expressed as the median fluorescence
intensity minus background (MFI-BG). For detection of cardiolipin-spe-
cific IgG or IgM, specimens were run separately with cardiolipin-coupled
microbeads, followed by biotinylated anti-human IgG or IgM detection
antibody (Southern Biotech) at 50 ng/well. Detection with streptavi-
din-PE was performed as described above.
Statistical analysis. Statistical analyses were performed using Graph-
Pad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA). Mann-
Whitney tests were used for comparison among all three countries. We
used a log-normal regression model to test whether the median fluores-
cent intensity of MBA assays increased as a function of RPR titer. Linear
regression analysis of data from three countries combined was performed
using best-fit values of a log-normal regression model. R2 was tested by
goodness-of-fit analysis, and differences in slopes were calculated with
Fisher’s exact test.
RESULTS
Demographic and standard serology testing. Overall, 592 speci-
mens were tested: 255 from Ghana, 169 from Vanuatu, and 168
from PNG. Of the 592 specimens, 241 (41.1%) had positive RPR
and TPP(H)A results, 88 (14.9%) were positive for TPP(H)A
alone, 6 (1.0%) had positive RPR but negative TPP(H)A results,
and the remaining 254 specimens (42.9%) were nonreactive in
both the treponemal and nontreponemal reference tests.
Sensitivity and specificity of antigens. Receiver operator
curves were generated for each antigen using a panel of pediatric
sera from countries in which yaws was not endemic for the nega-
tive population and sera or blood spots from children 15 years
old from Ghana and Vanuatu who were TPPA positive and had
RPR values of R04 for the positive population. A cutoff that
maximized combined sensitivity and specificity was set at 4,702
MFI for rp17 (100% sensitive, 100% specific) and 285 MFI for
TmpA (97% sensitive, 100% specific).
The overall sensitivity of the rp17 assay compared to TPP(H)A
was 90.1% (95% confidence interval [CI], 86.84 to 93.28), with a
specificity of 97.6% (95% CI, 95.79 to 99.51) (Table 1). The TmpA
assay showed a sensitivity of 67.47% (95% CI, 62.43 to 72.51) and
a specificity of 99.2% (95% CI, 98.14 to 100) versus TPP(H)A. The
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overall sensitivity of the rp17 assay compared with RPR was 94.8%
(95% CI, 92.02 to 97.54), while the sensitivity for TmpA com-
pared to RPR was 79.9% (95% CI, 74.94 to 84.9). The overall
specificity of rp17 compared to the RPR assay was 92.7% (95% CI,
89.59 to 95.76), and the specificity of TmpA compared to RPR was
98.2% (95% CI, 96.57 to 99.76). The country-specific sensitivities
and specificities of rp17 and TmpA-specific antibody reactivity
against TPP(H)A or RPR testing are shown in Table 1. Specificities
were not calculated for specimens from PNG because only a con-
venience sample of TPP(H)A-positive specimens was provided
for testing and analysis.
Evaluation of treponemal antigens and cardiolipin on an
MBA assay. Specimens were stratified based on their combined
reactivity in TPP(H)A and RPR assays and compared to responses
obtained against rp17 and TmpA in the MBA assays. Among spec-
imens testing dual negative by TPP(H)A and RPR, 97.6% were
nonreactive against rp17, and 99.2% were nonreactive against
TmpA (Fig. 1). The majority of TPP(H)A/RPR dual-positive spec-
imens were reactive against rp17 (88.5%) and TmpA (70.6%). For
TPP(H)A-positive/RPR-negative specimens, 75.0% had rp17-
specific responses, whereas only 30.7% had TmpA-specific re-
sponses. The median MFI-BG for TmpA responses was lower in
the TPP(H)A-positive/RPR-negative specimens (MFI-BG  101)
than in the dual-positive specimens (MFI-BG  4,315).
Carboxylated cardiolipin was coupled to carboxylated micro-
spheres using two different diamine linkers: poly-L-lysine and ca-
davarine. Cardiolipin-coated beads were run with control sera
from known RPR-positive and RPR-negative individuals (see Fig.
S1 in the supplemental material). When a cadavarine diamine
linker was used, the MFI-BG of IgM responses to cardiolipin in
RPR-positive serum decreased with increasing serum dilutions
(1:6, 1:25, and 1:100). Anticardiolipin responses in the RPR-neg-
ative group were not detectable at the 1:400 dilution (see Fig. S1).
Similar results were observed when poly-L-lysine was used as the
diamine linker (data not shown). Anticardiolipin IgG responses
were not detectable at any serum dilution (see Fig. S1).
Comparison of treponemal antibody responses to RPR ti-
ters. Specimens were stratified by RPR titer and then compared to
the intensity of MFI-BG of rp17 and TmpA responses. Linear
regression analysis showed a positive correlation (R2  0.41; P 
0.0001) between TmpA MFI-BG levels and RPR titers (Fig. 2). A
positive correlation between rp17 MFI-BG levels and RPR titers
was also observed (R2  0.10; P  0.0001) (Fig. 2). The slope of the
regression line for TmpA (131.0 	 8.5) was significantly steeper
than that for rp17 (84.8 	 12.7; P  0.0034).
DISCUSSION
In communities from three different countries in which yaws is
endemic, antibody responses against the treponemal recombinant
antigens rp17 and TmpA were detected with high sensitivity and
specificity compared to responses with standard reference tests.
Specimens with negative RPR titers typically had low-intensity
TABLE 1 Sensitivities and specificities of antibody responses against treponemal antigens rp17 and TmpA to standard serological testsa
N rp17 v TPP(H)A (95% CI) TmpA v TPP(H)A (95% CI) rp17 v RPR (95% CI) TmpA v RPR (95% CI)
Sensitivity
Total 587 90.1 (86.84–93.28) 67.47 (62.43–72.51) 94.8 (92.02–97.54) 79.9 (74.94–84.9)
Ghana 255 95.0 (90.73–99.27) 89.0 (82.87–96.98) 98.9 (96.67–100) 96.6 (92.88–100)
Vanuatu 169 89.9 (82.72–96.98) 50.7 (38.92–62.52) 88.7 (80.83–96.59) 56.5 (44.11–68.79)
PNG 163 87.1 (81.97–92.25) 61.3 (53.87–68.83) 94.9 (90.54–99.26) 79.6 (71.61–87.57)
Specificity
Total 424 97.6 (95.79–99.51) 99.2 (98.14–100) 92.7 (89.59–95.76) 98.2 (96.57–99.76)
Ghana 255 96.8 (93.99–99.55) 98.7 (96.93–100) 92.8 (88.83–96.71) 97.0 (94.39–99.59)
Vanuatu 169 99.0 (97.05–100) 100.0 (100–100) 92.5 (87.54–97.5) 100.0 (94.07–100)
a Dried blood spots or serum were tested for antitreponemal antibodies using a Luminex assay and compared to field-based determination of TPP(H)A or RPR positivity. The
number of specimens testing positive or negative by each assay is listed by country. 95% confidence intervals (CIs) are shown in parentheses. PNG specimens were not included in
the specificity analysis because only TPHA-positive specimens were sent for testing.
FIG 1 Reactivity of rp17 and TmpA by reactivity to standard diagnostics. Responses of TPP(H)A
/RPR
, TPP(H)A/RPR
, and TPP(H)A/RPR individuals
to rp17 (left) and TmpA (right). Symbols represent data from a single individual. Individuals were grouped by reactivity to standard treponemal (TPPA or
TPHA) or nontreponemal (RPR) diagnostics tests. Median fluorescent intensities against rp17 and TmpA treponemal antigens were plotted. Dotted lines denote
cutoffs for positive responses. n  586; 6 specimens testing TPP(H)A
/RPR were not included.
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values for TmpA, which may reflect a loss of TmpA-specific anti-
bodies over time. In addition, we found a positive correlation
between increasing RPR titers and increasing TmpA levels on an
MBA assay, supporting that this treponemal antibody response
might increase or decline in concert with RPR. Our data show that
an MBA assay using two treponemal antigens, rp17 as a marker of
historical infection and TmpA as a marker of recent infection, has
the potential to be used as a single high-throughput screening tool
for yaws programs.
Previous studies showed a decrease in TmpA titers in syphilis
patients 3 to 9 months after treatment (11) and that specimens
that were nonreactive in the nontreponemal VDRL test had lower
TmpA levels than seen in VDRL-reactive specimens (12). The cur-
rent report provides further evidence that antibody responses
against TmpA are associated with low RPR titers and therefore
may potentially be used to differentiate active or recent infections
from past infection.
Surprisingly, there was also a lower intensity of rp17 MFI-BG
in the TPP(H)A-positive/RPR-negative and R1- and R2-positive
populations than with higher RPR titers. It is possible that even the
traditional long-lived anti-treponemal antibody response wanes
to some extent after resolution of infection but that this declining
response is detectable only on highly sensitive assays, such as the
MBA used in this study. The correlation between RPR titers and
TmpA MFI-BG was much stronger than for rp17 MFI-BG, as the
differences in the slopes of the regression lines were significant.
While anti-TmpA responses approached seroreversion, anti-rp17
responses remained at high levels even at the 1:400 dilution used
in this assay.
The ability to use TmpA to track recent or active infection
would be valuable to programs, since this antigen can be incorpo-
rated into a high-throughput multiplex assay that can simultane-
ously measure responses to multiple analytes (i.e., to screen for
several infections) in a single run. Therefore, a change in diagnos-
tic procedure from the currently implemented RPR test that mea-
sures one specimen at a time to an MBA using TmpA has clear
advantages. The BioPlex 2200 system, an automated multiplex
instrument, was previously evaluated for automated syphilis diag-
nostics using commercially available treponemal antigen-coated
microbeads to detect IgG for rp17 and other treponemal antigens
and IgM against cardiolipin (13, 14). However, using this system
for large-scale screening during a worldwide yaws eradication
campaign presents several problems. First, this system still re-
quires separate runs for the treponemal and nontreponemal anti-
gens due to different secondary antibody requirements (detection
of IgG versus IgM) and different dilutions needed to detect IgG
versus IgM. In contrast, the ability to use anti-TmpA IgG testing
for recent or active infection allows this test to be integrated with
the treponemal antigen testing for yaws. Additionally, the cost per
unit for the BioPlex 2200 and the corresponding commercially
available reagents is high. In-house antigen-bead couplings are
cost-effective and allow for use with a more affordable and adapt-
able multiplex-capable instrument, such as the Luminex or Mag-
Pix system. The methodology described herein would further al-
low the integration of yaws surveillance with other disease
surveillance programs or vaccine coverage surveys, which use se-
rology testing and often also focus on young children.
One limitation of this study was the relatively small number of
specimens tested with the lowest RPR titers (especially R2, for
which n  8), which indicated very low or waning anticardiolipin
levels. Having more of these specimens in future studies will allow
us to get better estimates of TmpA antibody levels in this range,
which in turn will increase the confidence that TmpA responses
wane along with RPR titers. Another limitation is that we did not
follow up with individuals after treatment over time, which, in our
view, is the most accurate way to assess the dynamics of serology
tests before and after treatment. Studies are being planned to eval-
uate the change in TmpA titers after treatment in individuals.
The renewal of the yaws eradication program has catalyzed
advances in diagnostic tools for treponemal infections. Current
serological diagnostics fulfill some but not necessarily all program
needs. A combined rapid test, the dual-path platform syphilis as-
say, which detects both treponemal and nontreponemal antibod-
ies, has been evaluated for the diagnosis of yaws and has shown
high accuracy to confirm yaws cases in the field (15, 16). This type
of field-deployable test will be critical for village-level evaluations
during intensive programs monitoring both clinical cases and se-
rologically positive cases of yaws over the course of 3 years where
the program has been implemented (6). In contrast, a large-scale
screening tool, such as that presented here, may benefit yaws erad-
ication programs as a gross mapping tool to help determine where
to conduct intensive screenings, since implementing intensive vil-
lage-level surveillance in all countries in which yaws was previ-
ously endemic, current status unknown, is impractical. In addi-
FIG 2 Linear regression analysis of anti-treponemal antibody levels against RPR titers. RPR titers are plotted against antibody responses against rp17 (left) or
TmpA (right). Only data from TPP(H)A individuals were used in the analysis. Dots represent data from a single individual. The x axes are labeled with RPR
titers, and y axes show MFI-BG of anti-treponemal antibody responses. Dotted lines represent 95% confidence intervals. Slopes of the two curves are significantly
different (P  0.0034). Number of specimens for each group: 88 RPR negative, 24 R1, 8 R2, 24 R4, 41 R8, 32 R16, 41 R32, 46 R64, and 30 R128.
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tion, such a tool that can differentiate previous from current
infection, if applied in appropriate age groups (children aged 5
years), might be used to assess ongoing transmission. WHO cri-
teria to certify interruption of transmission include no RPR sero-
reactors among children aged 5 years, given that seroreactivity
in young children can indicate recent infection as they are new
entrants in the potential pool of susceptible individuals. In sum-
mary, this multiplex-based antibody testing may be useful during
the first stage of the program to direct mapping efforts and during
the endgame to certify the elimination of yaws.
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